


Delve Health and Bionabu Partner to Transform Clinical Trials with Al-Powered Video Solutions

Enhancing Patient Engagement and Study Site Education with Al-Driven Multilingual Video Content

MINNEAPOLIS, MN, UNITED STATES, February 4, 2025 /EINPresswire.com/ -- Minneapolis, Minnesota – The future of clinical trials is here—where AI, automation, and decentralization converge to make research more accessible and engaging than ever before.

Delve Health, a leader in <u>decentralized</u> <u>clinical trials</u> (DCTs), has partnered with Bionabu, an innovator in Al-powered



video technology, to transform eConsent, patient awareness, and study site education. Through this collaboration, Bionabu's advanced Al-driven, personalized video solutions will be integrated into Delve Health's <u>Clinical StudyPal</u> platform, enhancing accessibility, comprehension, and engagement in clinical trials worldwide.



At Delve Health, we believe in breaking down barriers to clinical trial participation. By incorporating Al-driven video solutions, we're enhancing how patients, research sites, and sponsors engage"

Wessam Sonbol

Addressing a Critical Challenge in Clinical Trials
Patient dropout rates, low engagement, and site training
inefficiencies remain critical challenges in clinical research.
Traditional text-based study materials often fail to
effectively communicate complex trial information to
diverse patient populations, while also providing limited
resources for study teams. This leads to confusion,
protocol deviations, delays, and increased costs.

☐ Studies show that video-based patient education can improve comprehension by 70% and reduce study dropout

rates by up to 30%. By leveraging Al-powered, multilingual video content, Clinical StudyPal is setting a new standard for clinical trial engagement—now enhanced with eConsent innovations and real-time wearable data integration.

Clinical StudyPal: The Future of Decentralized Trials

Delve Health's Clinical StudyPal is an end-to-end decentralized clinical trial (DCT) platform designed to streamline every aspect of clinical research, from patient screening to remote monitoring. It enables seamless engagement between patients, research sites, and sponsors through mobile-first, Al-driven tools that enhance trial accessibility and efficiency.

With the integration of Bionabu's Al-powered video solutions, Clinical StudyPal will now further enhance:

□ eConsent: Interactive, multilingual videos to simplify informed consent and improve patient comprehension—integrated with TeleVisit for real-time engagement.

□ Patient Awareness: Al-generated video personalized guides to ensure patients and their families fully understand trial protocols, reducing confusion and dropouts.

□ Site Education: Personalized onboarding and study-specific training for research teams, improving consistency and compliance in a decentralized trial environment.

Key Benefits of the Collaboration

- ☐ Al-powered, personalized video content tailored for eConsent, patient awareness, and site onboarding.
- ☐ Multilingual support to maximize accessibility for diverse populations.
- ☐ Seamless integration with Clinical StudyPal for a streamlined, user-friendly experience.
- ☐ HIPAA, GDPR, FDA, and EMA compliance for secure and ethical trial communication.
- ☐ Scalable, cost-effective, and consistent content delivery across global clinical trials.

Empowering Patients & Research Teams Through AI

"At Delve Health, we believe in breaking down barriers to clinical trial participation. By incorporating Al-driven video solutions, we're enhancing how patients, research sites, and sponsors engage with trial information—making it more personalized, scalable, and data-driven," said Wessam Sonbol, CEO at Delve Health.

"Our collaboration with Delve Health is a game-changer in clinical trials," added Ina Burgstalle, CEO at Bionabu. "With Al-powered video content, we are transforming how study participants and research teams receive and retain critical trial information—leading to better engagement, improved compliance, and higher retention rates."

Shaping the Future of Clinical Trials

This partnership marks just the beginning of Delve Health and Bionabu's commitment to reshaping clinical trials through AI, automation, eConsent, and remote patient engagement. As eConsent evolves beyond static digital forms, AI-driven video content will play a key role in enhancing patient understanding and engagement. Combined with real-time data collection

from wearables, these advancements will create a seamless, data-driven ecosystem where patients can participate in trials with greater ease and confidence.

Join the Future of Decentralized Trials

☐ Are you a research sponsor, trial site, or investigator looking to enhance trial efficiency through Al-powered eConsent, video-based patient engagement, and real-time wearable data integration? Let's discuss how these innovations can improve your study outcomes.

☐ Contact us today at contact@delvehealth.com or visit <u>www.delvehealth.com</u> to learn more about Clinical StudyPal and the future of decentralized trials.

Wessam Sonbol
Delve Health
+1 952-200-6228
email us here
Visit us on social media:
LinkedIn
Instagram
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/782913315

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.